Aims To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for diabetic macular oedema (DMO) from a multicentre database.
Methods Structured clinical data were anonymised and extracted from an electronic medical record from 19 participating UK centres: age at first injection, ETDRS visual acuity (VA), number of injections, ETDRS diabetic retinopathy (DR) and maculopathy grade at baseline and visits. The main outcomes were change in mean VA from baseline, number of injections and clinic visits and characteristics affecting VA change and DR grade.
Results Data from 12 989 clinic visits was collated from baseline and follow-up for 3103 eyes. Mean age at first treatment was 66 years. Mean VA (letters) for eyes followed at least 2 years was 51.1 (SD=19.3) at baseline, 54.2 (SD: 18.6) and 52.5 (SD: 19.4) at 1 and 2 years, respectively. Mean visual gain was five letters. The proportion of eyes with VA of 72 letters or better was 25% (baseline) and 33% (1 year) for treatment naïve eyes. Eyes followed for at least 6 months received a mean of 3.3 injections over a mean of 6.9 outpatient visits in 1 year.
Conclusions In a large cohort of eyes with DMO treated with ranibizumab injections in the UK, 33% of patients achieved better than or equal to 6/12 in the treated eye at 12 months compared with 25% at baseline. The mean visual gain was five letters. Eyes with excellent VA at baseline maintain good vision at 18 months.
- Treatment Medical
- Treatment Surgery
- Public health
Statistics from Altmetric.com
Twitter Follow David Crabb @crabblab
Collaborators UK AMD and DR EMR Users Group: Contributing Centres and Lead Clinician at each centre: Belfast Health and Social Care Trust, Professor Usha Chakravarthy; Calderdale and Huddersfield NHS Foundation Trust, Mrs Rehna Khan; Cambridge University Hospitals NHS Foundation Trust, Mr Jong Min Ong; Central Manchester University Hospitals NHS Foundation Trust, Mr Sajjad Mahmood; Frimley Park Hospital NHS Foundation Trust, Mrs Geeta Menon; Gloucestershire Hospitals NHS Foundation Trust, Mr Robert Johnston; Heart of England NHS Foundation Trust, Miss Saher Al-Husainy; Hinchingbrooke Health Care NHS Trust, Ms Toks Akerele; Hull and East Yorkshire Hospitals NHS Foundation Trust, Miss Louise Downey; Leeds Teaching Hospitals NHS Trust, Mr Martin McKibbin; Mid Yorkshire Hospitals NHS Trust, Mr Atul Varma; Moorfields Eye Hospital at Bedford Hospital, Mr Aires Lobo; Northern Devon Healthcare NHS Trust, Dr Elizabeth Wilkinson; Peterborough and Stamford Hospitals NHS Foundation Trust, Mr Alan Fitt; Sheffield Teaching Hospitals NHS Foundation Trust, Mr Christopher Brand; University Hospitals Birmingham NHS Foundation Trust, Miss Marie Tsaloumas; University Hospitals Bristol NHS Foundation Trust, Miss Clare Bailey; Warrington and Halton Hospitals NHS Foundation Trust, Miss Kaveri Mandal; Wirral University Teaching Hospital NHS Foundation Trust, Mr Vineeth Kumar; Wrightington, Wigan and Leigh NHS Foundation Trust, Mr Salim Natha.
Contributors All the authors have contributed to the planning, conduct and reporting of the work described in the article.
Funding This work was supported in part by an unrestricted research award by Novartis Pharmaceuticals. This research has received a proportion of its funding from the Department of Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology.
Competing interests RJ is the Medical Director of Medisoft, the Electronic Medical Record software provider from which data were extracted.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.